covery and vival of patients with moderate to severe acute spiratory distress syndrome (ARDS) due to OVID-19: a multicenter, single-arm, Phase IV itolizumab rial: .

Background: Itolizumab, an anti-CD6 monoclonal antibody, down-regulates COVID-19-mediated inflammation and the acute effects of cytokine release syndrome. This study aimed to evaluate the safety and efficacy of itolizumab in hospitalized COVID-19 patients with PaO/FiO ratio (PFR) ≤200 requiring oxygen therapy.

Research Design And Methods: This multicenter, single-arm, Phase 4 study enrolled 300 hospitalized adults with SARS-CoV-2 infection, PFR ≤200, oxygen saturation ≤94%, and ≥1 elevated inflammatory markers from 17 COVID-19 specific tertiary Indian hospitals.

Outcome of therapeutic plasma exchange in Myasthenia gravis patients.

Aims: The aim of this study was to evaluate the indications, adverse reactions, and outcome of therapeutic plasma exchange (TPE) in myasthenia gravis (MG) patients.

Settings And Design: Retrospective Observational study.

Methods And Material: A total of 18 patients of MG had undergone 18 cycles and 87 session of TPE at our Institution, a tertiary care center in Western India.

Evaluation of Non-polar Composition in Leaves by Gas Chromatography and Mass Spectrometry.

Background: Plumbago zeylanica plant belongs to Plumbaginaceae. The plant is reported for many pharmacological activities.

Aim: The objective of the study was to identify fatty acids and non-polar chemical compounds in Plumbago zeylanica leaves.

Dopa responsive burning mouth syndrome: restless mouth syndrome or oral variant of restless legs syndrome?

Burning mouth syndrome (BMS) is an oral dysesthesia presenting as a burning sensation of the tongue and other oral and perioral mucosae. A painful symptomatology in different bodily regions (extraoral) may also be a common feature in patient with BMS. The management of BMS is challenging and there is no clear guideline for the management of idiopathic BMS.